Paper - WANFANG MED ONLINE

You Position: Home > Paper

Arachidonic acid metabolism in liver glucose and lipid homeostasis

( views:8, downloads:0 )

Author:: No author available

Journal Title:: Acta Physiologica Sinica

Issue:: 4

DOI:: 10.13294/j.aps.2021.0052

Key Word:: 花生四烯酸;肝脏;代谢;脂质介质;代谢性疾病

Abstract：花生四烯酸(arachidonic acid,AA)是一种ω-6多不饱和脂肪酸,在生物体内主要是以磷脂的形式存在于细胞膜上.AA在细胞内主要通过环氧合酶(cyclooxygenase,COX)途径、脂氧合酶(lipoxygenases,LOX)途径、细胞色素P450单氧化酶(cytochrome P450 monooxygenase,CYP450)途径等进行代谢.糖脂代谢的稳态调控是维持机体基本生命活动的基础,肝脏是糖脂代谢调控的中枢器官.肝脏糖脂代谢紊乱与2型糖尿病、非酒精性脂肪性肝病等代谢性疾病的发生和发展密切相关.己有研究表明AA代谢与肝脏糖脂代谢紊乱有密切的关系.本文就AA代谢在肝脏糖脂代谢稳态调控中的作用及其作为脂肪肝和胰岛素抵抗等代谢性疾病治疗靶点的价值作一综述.

Reference

[1]Simmons DL,Botting RM,Hla T.Cyclooxygenase isozymes: the biology of prostaglandin synthesis and inhibition.[J].2004,56(3).
[2]Amada H,Kameo K,Ishii T,etc.Discovery of a N'-hydroxyphenylformamidine derivative HET0016 as a potent and selective 20-HETE synthase inhibitor.[J].2001,11(23).
[3]Wang Xiaojing,Li Lan,Wang Hongwu,etc.Epoxyeicosatrienoic acids alleviate methionine‐choline‐deficient diet–induced non‐alcoholic steatohepatitis in mice[J].2019,90(3).
[4]Manikandan, Palrasu,Nagini, Siddavaram.Cytochrome P450 Structure, Function and Clinical Significance: A Review[J].2018,19(1).
[5]Claudia O. Zein,Rocio Lopez,Xiaoming Fu,etc.Pentoxifylline decreases oxidized lipid products in nonalcoholic steatohepatitis: New evidence on the potential therapeutic mechanism[J].2012,56(4).
[6]Witters LA,Unger RH,Gonzales F,etc.PPAR alpha is necessary for the lipopenic action of hyperleptinemia on white adipose and liver tissue.[J].2002,99(18).
[7]Abdelmegeed,M.A.,Gonzalez,F.J.,Yoo,S.-H.,etc.Critical role of cytochrome P450 2E1 (CYP2E1) in the development of high fat-induced non-alcoholic steatohepatitis[J].2012,57(4).
[8]Kathirvel E,Chen P,Morgan K,etc.Oxidative stress and regulation of anti-oxidant enzymes in cytochrome P4502E1 transgenic mouse model of non-alcoholic fatty liver.[J].2010,25(6).
[9]Chen,Liu,Bai,etc.Celecoxib attenuates liver steatosis and inflammation in non-alcoholic steatohepatitis induced by high-fat diet in rats[J].2011,4(5).
[10]Li, Xuguang,Zhao, Gang.20-Hydroxyeicosatetraenoic Acid Impairs Endothelial Insulin Signaling by Inducing Phosphorylation of the Insulin Receptor Substrate-1 at Ser<sup>616</sup>.[J].2014,9(4).
[11]M J, Yin,Y, Yamamoto,R B, Gaynor.The anti-inflammatory agents aspirin and salicylate inhibit the activity of I(kappa)B kinase-beta.[J].1998,396(6706).
[12]Tilg Herbert,Moschen Alexander R..Inflammatory Mechanisms in the Regulation of Insulin Resistance[J].2008,14(3-4).
[13]Motino, Omar,Frances, Daniel E.,Mayoral, Rafael,etc.Regulation of MicroRNA 183 by Cyclooxygenase 2 in Liver Is DEAD-Box Helicase p68 (DDX5) Dependent: Role in Insulin Signaling[J].2015,35(14).
[14]Ricciotti E,FitzGerald GA.Prostaglandins and inflammation.[J].2011,31(5).
[15]Brea Contreras, Rocio,Garcia-Monzon, Carmelo,Frances, Daniel E.,etc.Cyclooxygenase-2 expression in hepatocytes attenuates non-alcoholic steatohepatitis and liver fibrosis in mice[J].2016,1862(9).
[16]Izzo, A.A.,Deutsch, D.G..Unique pathway for anandamide synthesis and liver regeneration[J].2011,108(16).
[17]Ceddia, Ryan P.,Lee, DaeKee,Maulis, Matthew F.,etc.The PGE(2) EP3 Receptor Regulates Diet-Induced Adiposity in Male Mice[J].2016,157(1).
[18]Kathirvel E,French SW,Morgan K.Overexpression of liver-specific cytochrome P4502E1 impairs hepatic insulin signaling in a transgenic mouse model of nonalcoholic fatty liver disease.[J].2009,21(9).
[19]Wells, Michael A.,Vendrov, Kimberly C.,Edin, Matthew L.,etc.Characterization of the Cytochrome P450 epoxyeicosanoid pathway in non-alcoholic steatohepatitis[J].2016,125.
[20]Woolsey, Sarah J.,Mansell, Sara E.,Kim, Richard B.,etc.CYP3A Activity and Expression in Nonalcoholic Fatty Liver Disease[J].2015,43(10).
[21]Titos E,Deulofeu R,Horrillo R,etc.5-Lipoxygenase Activating Protein Signals Adipose Tissue Inflammation and Lipid Dysfunction in Experimental Obesity.[J].2010,184(7).
[22]Puneet Puri,Rebecca A. Baillie,Michelle M. Wiest,etc.A lipidomic analysis of nonalcoholic fatty liver disease[J].2007,46(4).
[23]Mukhopadhyay, B.,Cinar, R.,Yin, S.,etc.Hyperactivation of anandamide synthesis and regulation of cell-Cycle progression via cannabinoid type 1 (CB1) receptors in the regenerating liver[J].2011,108(15).
[24]Jun Yu,Jun Yu,Emilia Ip,etc.COX‐2 induction in mice with experimental nutritional steatohepatitis: Role as pro‐inflammatory mediator[J].2006,43(4).
[25]Pei-Chi, Chan,Fone-Ching, Hsiao,Hao-Ming, Chang,etc.Importance of adipocyte cyclooxygenase-2 and prostaglandin E2-prostaglandin E receptor 3 signaling in the development of obesity-induced adipose tissue inflammation and insulin resistance.[J].2016.
[26]J H, Hartwig,G M, Bokoch,C L, Carpenter,etc.Thrombin receptor ligation and activated Rac uncap actin filament barbed ends through phosphoinositide synthesis in permeabilized human platelets.[J].1995,82(4).
[27]Haihong, Zong,Michal, Armoni,Chava, Harel,etc.Cytochrome P-450 CYP2E1 knockout mice are protected against high-fat diet-induced obesity and insulin resistance.[J].2012,302(5).
[28]Randhawa PS,Shulman GI,Hundal RS,etc.Mechanism by which high-dose aspirin improves glucose metabolism in type 2 diabetes.[J].2002,109(10).
[29]Xu J,Wong C.A computational screen for mouse signaling pathways targeted by microRNA clusters.[J].2008,14(7).
[30]Morrow JD,Fam SS.The isoprostanes: unique products of arachidonic acid oxidation-a review.[J].2003,10(17).
[31]Castro-Sanchez, Luis,Fernandez-Alvarez, Ana,Frances, Daniel E.,etc.Hepatic Cyclooxygenase-2 Expression Protects Against Diet-Induced Steatosis, Obesity, and Insulin Resistance[J].2015,64(5).
[32]Fitzpatrick FA.Cyclooxygenase enzymes: regulation and function.[J].2004,10(6).
[33]Gonzalez FJ,Robertson GR,Farrell GC,etc.CYP2E1 and CYP4A as microsomal catalysts of lipid peroxides in murine nonalcoholic steatohepatitis.[J].2000,105(8).
[34]Trostchansky A,Ferreira A,Ferrari M,etc.Synthesis, isomer characterization, and anti-inflammatory properties of nitroarachidonate.[J].2007,46(15).
[35]Rigoli RM,Singh R,Schattenberg JRM,etc.Hepatocyte CYP2E1 overexpression and steatohepatitis lead to impaired hepatic insulin signaling[J].2005,280(11).
[36]Rumore MM,Kim KS.Potential role of salicylates in type 2 diabetes.[J].2010,44(7).
[37]Arvind, Ashwini,Osganian, Stephanie A.,Sjoquist, Julia A.,etc.Epoxygenase-Derived Epoxyeicosatrienoic Acid Mediators Are Associated With Nonalcoholic Fatty Liver Disease, Nonalcoholic Steatohepatitis, and Fibrosis[J].2020,159(6).
[38]Wu,J.,Liu,X.,Lai,G.,etc.20-HETE induces hyperglycemia through the cAMP/PKA-PhK-GP pathway[J].2012,26(11).
[39]Tsujimoto, Shunsuke,Kishina, Manabu,Koda, Masahiko,etc.Nimesulide, a cyclooxygenase-2 selective inhibitor, suppresses obesity-related non-alcoholic fatty liver disease and hepatic insulin resistance through the regulation of peroxisome proliferator-activated receptor gamma[J].2016,38(3).
[40]Cho, Sung-Joon,Kim, Sang-Bum,Cho, Hyun-Jong,etc.Effects of Nonalcoholic Fatty Liver Disease on Hepatic CYP2B1 and in Vivo Bupropion Disposition in Rats Fed a High-Fat or Methionine/Choline-Deficient Diet[J].2016,64(27).
[41]Yan, Shuai,Tang, Juan,Zhang, Yuyao,etc.Prostaglandin E-2 Promotes Hepatic Bile Acid Synthesis by an E Prostanoid Receptor 3-Mediated Hepatocyte Nuclear Receptor 4 alpha/Cholesterol 7 alpha-Hydroxylase Pathway in Mice[J].2017,65(3).
[42]Yan,S.,Zhang,Q.,Zhong,X.,etc.I prostanoid receptor-mediated inflammatory pathway promotes hepatic gluconeogenesis through activation of pka and inhibition of AKT[J].2014,63(9).
[43]Rohitash Jamwal,Suzanne M. de la Monte,Ken Ogasawara,etc.Nonalcoholic Fatty Liver Disease and Diabetes Are Associated with Decreased CYP3A4 Protein Expression and Activity in Human Liver[J].2018,15(7).
[44]Yinna Wang,Shasha Zhang,Guangzhi Chen,etc.CYP2J2 overexpression attenuates nonalcoholic fatty liver disease induced by high-fat diet in mice[J].2015,308(1 Pt.1).
[45]Sacerdoti, D.,Gatta, A.,McGiff, J. C..Role of cytochrome P450-dependent arachidonic acid metabolites in liver physiology and pathophysiology[J].2003,72(1).
[46]Hellmann J,Tang Y,Jala VR,etc.Deficiency of the Leukotriene B4 Receptor, BLT-1, Protects against Systemic Insulin Resistance in Diet-Induced Obesity.[J].2011,187(4).
[47]Puneet Puri,Michelle M. Wiest,Onpan Cheung,etc.The plasma lipidomic signature of nonalcoholic steatohepatitis[J].2009,50(6).
[48]Schuck, Robert N.,Zha, Weibin,Edin, Matthew L.,etc.The Cytochrome P450 Epoxygenase Pathway Regulates the Hepatic Inflammatory Response in Fatty Liver Disease.[J].2014,9(10).
[49]Naoki Tanaka,Tsutomu Matsubara,Kristopher W. Krausz,etc.Disruption of phospholipid and bile acid homeostasis in mice with nonalcoholic steatohepatitis[J].2012,56(1).
[50]Kuhn, Hartmut,Banthiya, Swathi,van Leyen, Klaus.Mammalian lipoxygenases and their biological relevance[J].2015,1851(4).
[51]Zoe Hall,Nicholas J. Bond,Tom Ashmore,etc.Lipid zonation and phospholipid remodeling in nonalcoholic fatty liver disease[J].2017,65(4).
[52].Arachidonic Acid Metabolites in Cardiovascular and Metabolic Diseases.[J].2018,19(11).
[53]Noriyuki Miyata,Kazuo Taniguchi,Takayuki Seki,etc.HET0016, a potent and selective inhibitor of 20‐HETE synthesizing enzyme[J].2001,133(3).
[54]Wen Su,Yang Wang,Xiao Jia,etc.Comparative proteomic study reveals 17β-HSD13 as a pathogenic protein in nonalcoholic fatty liver disease[J].2014,111(31).
[55]M, Yuan,N, Konstantopoulos,J, Lee,etc.Reversal of obesity- and diet-induced insulin resistance with salicylates or targeted disruption of Ikkbeta.[J].2001,293(5535).
[56]Marcin,Banaszczak,Dominika,Maciejewska,Arleta,Drozd,etc.5-Lipooxygenase Derivatives as Serum Biomarkers of a Successful Dietary Intervention in Patients with NonAlcoholic Fatty Liver Disease.[J].2020,56(2).
[57]D, Schlondorff.Renal prostaglandin synthesis. Sites of production and specific actions of prostaglandins.[J].1986,81(2B).
[58]Ann K, Daly.Relevance of CYP2E1 to Non-alcoholic Fatty Liver Disease.[J].2013,67.
[59]Edmond Changkyun Park,Seung Il Kim,Yeonhee Hong,etc.Inhibition of CYP4A reduces hepatic endoplasmic reticulum stress and features of diabetes in mice.[J].2014,147(4).
[60]K, Yamamoto,R, Yamashita,N, Ueda,etc.[Cyclooxygenase-1 and cyclooxygenase-2].[J].1996,19(6).
[61]Zhang, Xiaoyan,Li, Sha,Zhou, Yunfeng,etc.Ablation of cytochrome P450 omega-hydroxylase 4A14 gene attenuates hepatic steatosis and fibrosis[J].2017,114(12).
[62]Chung, Min-Yu,Bruno, Richard S.,Masterjohn, Christopher,etc.Green Tea Lowers Hepatic COX-2 and Prostaglandin E2 in Rats with Dietary Fat-Induced Nonalcoholic Steatohepatitis[J].2015,18(6).
[63]Martinez Clemente M,Ferre N,Titos E,etc.Disruption of the 12/15-lipoxygenase gene (Alox15) protects hyperlipidemic mice from nonalcoholic fatty liver disease.[J].2010,52(6).
[64]Claria J.Regulatory effects of arachidonate 5-lipoxygenase on hepatic microsomal TG transfer protein activity and VLDL-triglyceride and apoB secretion in obese mice.[J].2008,49(12).
[65]Martinez Clemente M,Gonzalez Periz,Ferre N.5-lipoxygenase deficiency reduces hepatic inflammation and tumor necrosis factor alpha-induced hepatocyte damage in hyperlipidemia-prone ApoE-null mice.[J].2010,51(3).
[66]Dominika Maciejewska,Piotr Ossowski,Arleta Drozd,etc.Metabolites of arachidonic acid and linoleic acid in early stages of non-alcoholic fatty liver disease-A pilot study[J].2015,121(Part B).
[67]Ryuichi, Mashima,Torayuki, Okuyama.The role of lipoxygenases in pathophysiology; new insights and future perspectives.[J].2015,6.